DBV Technologies | Stammkapital





Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 168.71M 104K 2025-09
Alnylam Pharmaceuticals USD 131.79M 130.49M 2025-09
Amarin USD 20.8M 28K 2025-09
BioCryst Pharmaceuticals USD 1.9M 3K 2023-09
BioMarin Pharmaceutical USD 192.1M 97K 2025-09
DBV Technologies USD 11.65M 1000 2025-03
Esperion Therapeutics USD 112K 11K 2023-09
Galectin Therapeutics USD 61K 0 2023-12
Halozyme Therapeutics USD 117.52M 98K 2025-09
Incyte USD 196.13M 2.01M 2025-09
Insmed USD 212.58M 210.76M 2025-09
Ionis Pharmaceuticals USD 161.14M 160.98M 2025-09
Neurocrine Biosciences USD 99.7M 700K 2025-09
PTC Therapeutics USD 79.93M 554K 2025-09
Sarepta Therapeutics USD 104.77M 7.06M 2025-09
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
United Therapeutics USD 42.9M 42.1M 2025-09


DBV Technologies Stammkapital - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.